.png)
EDO Convergent TV Outcomes
Report: Diabetes Pharmaceuticals
Diabetes pharmaceutical brands like Ozempic, Mounjaro, and Dexcom are becoming major players in convergent TV advertising. But which advertisers have been most successful at moving consumers closer to purchase?
In our latest Convergent TV Outcomes Report, we dive deep on how leading diabetes brands drove searches and website visits across linear and streaming TV throughout Q3 2024. Here’s some of what you’ll learn:
- Which brands were most effective at generating engagement across linear and streaming TV
- Which demographics and states were most — and least — engaged with diabetes pharmaceutical ads
- How diabetes pharmaceutical advertisers performed on streaming TV as compared to linear
- Which streaming platforms were most effective for top brands in the category
Take your brand’s next campaign to new heights with EDO’s TV Outcomes. Download our Diabetes Pharmaceuticals Convergent TV Outcomes Report for decision-worthy data you can count on.
Want to chat further?
Schedule some time with us to discuss how EDO can help you get the most out of your TV media buy.
About EDO
EDO, Inc. is a data and analytics company that measures predictive outcomes for Convergent TV. We are an innovative leader in applying world-class data science software and unique behavioral metrics to help our clients – marketers, TV networks, and agencies – generate greater value from their creative efforts and media decisions. EDO's reliable, investment-grade metrics align marketing with sales and finance, providing confidence in the efficacy of advertising dollars through detailed competitive, category, historical, and predictive insights.